Upgrade to SI Premium - Free Trial

Corbus Pharma (CRBP)

7.56 -0.45 (5.62%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/11/26)

Latest Headlines

Form 4 Corbus Pharmaceuticals For: Jun 02 Filed by: Saxena Nishant C June 3, 2026 5:37 PM - SEC Filing Form S-8 Corbus Pharmaceuticals May 29, 2026 4:51 PM - SEC Filing Form 8-K Corbus Pharmaceuticals For: May 26 May 26, 2026 8:56 AM - SEC Filing Corbus reports CRB-701 shows 42.9% response rate in oropharyngeal cancer May 26, 2026 7:00 AM - StreetInsider Corbus Pharmaceuticals Reports Updated CRB-701 Phase 1/2 Clinical Data Demonstrating Robust Activity in 2L Oropharyngeal and Cervical Cancers May 26, 2026 7:00 AM - Globe NewsWire Corbus Pharmaceuticals (CRBP) PT Raised to $44 at Mizuho May 26, 2026 6:42 AM - StreetInsider Form 4 Corbus Pharmaceuticals For: May 21 Filed by: Saxena Nishant C May 22, 2026 4:51 PM - SEC Filing Form 3 Corbus Pharmaceuticals For: May 21 Filed by: Saxena Nishant C May 22, 2026 4:50 PM - SEC Filing Corbus Pharmaceuticals (CRBP) PT Raised to $44 at Mizuho May 22, 2026 6:41 AM - StreetInsider Form 4 Corbus Pharmaceuticals For: May 19 Filed by: Kung Winston May 21, 2026 5:07 PM - SEC Filing Form 4 Corbus Pharmaceuticals For: May 19 Filed by: Jacques Rachelle Suzanne May 21, 2026 5:07 PM - SEC Filing Form 4 Corbus Pharmaceuticals For: May 19 Filed by: Jenkins John Kenneth May 21, 2026 5:06 PM - SEC Filing Form 4 Corbus Pharmaceuticals For: May 19 Filed by: Ben Yong May 21, 2026 5:06 PM - SEC Filing Form 4 Corbus Pharmaceuticals For: May 19 Filed by: Altmeyer Anne May 21, 2026 5:06 PM - SEC Filing Form 4 Corbus Pharmaceuticals For: May 19 Filed by: Pfeiffenberger Brent May 21, 2026 5:05 PM - SEC Filing Form 3 Corbus Pharmaceuticals For: May 13 Filed by: Pfeiffenberger Brent May 21, 2026 5:03 PM - SEC Filing Form 8-K Corbus Pharmaceuticals For: May 19 May 21, 2026 8:15 AM - SEC Filing Corbus names Nishant Saxena as chief business officer May 21, 2026 8:01 AM - StreetInsider Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call May 21, 2026 8:00 AM - Globe NewsWire Form SCHEDULE 13G/A Corbus Pharmaceuticals Filed by: Octagon Capital Advisors LP May 14, 2026 4:02 PM - SEC Filing Form 8-K Corbus Pharmaceuticals For: May 13 May 14, 2026 8:15 AM - SEC Filing Corbus Pharmaceuticals names Brent Pfeiffenberger to board of directors May 14, 2026 8:01 AM - StreetInsider Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors May 14, 2026 8:01 AM - Globe NewsWire Corbus Pharmaceuticals (CRBP) PT Lowered to $54 at Oppenheimer May 13, 2026 8:40 AM - StreetInsider Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences May 13, 2026 7:00 AM - Globe NewsWire Form 10-Q Corbus Pharmaceuticals For: Mar 31 May 12, 2026 4:51 PM - SEC Filing Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Jefferies May 12, 2026 4:02 PM - StreetInsider Corbus Pharmaceuticals (CRBP) PT Lowered to $33 at Jefferies May 12, 2026 4:02 PM - StreetInsider Corbus Pharma (CRBP) Misses Q1 EPS by 123c May 12, 2026 8:49 AM - StreetInsider Form 8-K Corbus Pharmaceuticals For: May 12 May 12, 2026 8:15 AM - SEC Filing Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update May 12, 2026 8:00 AM - Globe NewsWire Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ASCO 2026 May 5, 2026 8:00 AM - Globe NewsWire Guggenheim Starts Corbus Pharmaceuticals (CRBP) at Buy April 28, 2026 4:15 PM - StreetInsider Corbus Pharmaceuticals Announces Abstracts Accepted for Presentation at ASCO 2026 Featuring Updated Clinical Data for CRB-701 April 22, 2026 8:00 AM - Globe NewsWire Form DEFA14A Corbus Pharmaceuticals April 16, 2026 4:22 PM - SEC Filing Form 8-K Corbus Pharmaceuticals For: Apr 15 April 16, 2026 4:20 PM - SEC Filing Form 8-K Corbus Pharmaceuticals For: Apr 14 April 14, 2026 8:16 AM - SEC Filing Corbus Pharmaceuticals completes enrollment in obesity drug trial April 14, 2026 8:05 AM - StreetInsider Corbus Pharmaceuticals Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity April 14, 2026 8:01 AM - Globe NewsWire Jefferies on Corbus Pharmaceuticals (CRBP): FDA alignment de-risks, focus shifts to efficacy April 7, 2026 2:49 PM - StreetInsider Form 8-K Corbus Pharmaceuticals For: Apr 01 April 7, 2026 12:50 PM - SEC Filing Corbus Pharmaceuticals Announces Broad Alignment with FDA on Registration Path for CRB-701 in Second-Line HNSCC and Cervical Cancer April 7, 2026 12:29 PM - Globe NewsWire Corbus receives FDA alignment on registration path for cancer drug CRB-701 April 7, 2026 8:06 AM - StreetInsider Corbus Pharmaceuticals (CRBP) PT Raised to $40 at Mizuho April 6, 2026 6:40 AM - StreetInsider Form ARS Corbus Pharmaceuticals For: Dec 31 April 2, 2026 4:53 PM - SEC Filing Form DEFA14A Corbus Pharmaceuticals April 2, 2026 4:50 PM - SEC Filing Form DEF 14A Corbus Pharmaceuticals For: Apr 01 April 2, 2026 4:47 PM - SEC Filing Corbus Pharmaceuticals (CRBP) PT Raised to $40 at Mizuho April 2, 2026 8:49 AM - StreetInsider Form 424B3 Corbus Pharmaceuticals March 25, 2026 4:31 PM - SEC Filing Form EFFECT Corbus Pharmaceuticals March 23, 2026 6:07 AM - SEC Filing Corbus Pharmaceuticals to Participate in the BMO 2026 Metabolic Health Summit March 18, 2026 8:01 AM - Globe NewsWire Form S-3 Corbus Pharmaceuticals March 11, 2026 5:07 PM - SEC Filing Corbus Pharmaceuticals (CRBP) PT Raised to $57 at Oppenheimer March 10, 2026 8:12 AM - StreetInsider Form 10-K Corbus Pharmaceuticals For: Dec 31 March 9, 2026 4:16 PM - SEC Filing Form 8-K Corbus Pharmaceuticals For: Mar 09 March 9, 2026 7:43 AM - SEC Filing Corbus Pharma (CRBP) Misses Q4 EPS by 125c March 9, 2026 7:41 AM - StreetInsider Corbus Pharmaceuticals Reports Q4 and 2025 Financial Results and Provides a Corporate Update March 9, 2026 7:30 AM - Globe NewsWire Full Article List